Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer
Overview
The 18F-FDG-PET scan is currently being used for cancer diagnosis, staging, identifying hidden metastasis, and assessment of treatment responses in clinical oncology. Although there are important studies suggesting potential associations between PET-based parameters and oncologic outcomes, the calculation and official documentation of individual PET-based parameters might not be routine in clinical practice because these processes usually require time- and labor-consuming processes for the radiologists. In this study, the investigators prospectively determined clinical 18F-FDG-PET type according to degree of FDG-uptake in pancreatic cancer and compare oncologic outcomes between the types.
Full Title of Study: “Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer-Prospective Cohort Study”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Prospective
- Study Primary Completion Date: September 17, 2018
Interventions
- Device: PET-CT
- PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
Arms, Groups and Cohorts
- K-type
- FDG uptake in pancreatic cancer is similar to that of kidney
- non K-type
- FDG uptake in pancreatic cancer is lower than that of kidney
Clinical Trial Outcome Measures
Primary Measures
- Clinical PET type assessed by surgeons from preoperatively preformed PET imaging
- Time Frame: 1 week after surgery
- Three surgeons will review the preoperative PET imaging and each will determine the clinical PET type as either K-type or Non-K type. Inter-surgeon agreement of clinical PET type will be determined. Clinicopathologic characteristics between K-type and Non-K type will also be analyzed.
Secondary Measures
- Number of patients with recurrence of cancer or mortality from cancer following operation
- Time Frame: 3 years
Participating in This Clinical Trial
Inclusion Criteria
- Candidate for radical pancreatectomy due to pancreatic cancer without neoadjuvant treatment – Age between 20 years old and 80 years old – General performance status greater than 70 – Results of peroperative PET-CT available Exclusion Criteria:
- Unresectable, locally advance and metastatic pancreatic cancer – Patients not wanting operation – ASA score of greater than 3 – History of chronic alcoholism ot drug abuse – Lack of patient compliance – Patients not agreeing to enroll in the study. – Patients unable to understand and sign the study agreement. – History of neoadjuvant treatment
Gender Eligibility: All
Minimum Age: 20 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Yonsei University
- Provider of Information About this Clinical Study
- Sponsor
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.